Multiple Myeloma

The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…

Immunotherapies are at the forefront of myeloma treatment and there are many questions remaining. Defining high-risk is important when making…

Relapsed/refractory (R/R) multiple myeloma remains an incurable hematological malignancy with an unmet clinical need.  It is necessary to gain a…

Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple…

Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…

Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for…

Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence…

Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;…

The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing…

The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…

Over the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall…

Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared…